Meningococcal Vaccines Market Expected To Witness A Sustainable Growth at CAGR of 6.2% by 2030

Meningococcal Vaccines Industry Overview

The global meningococcal vaccines market size was valued at USD 2.88 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030.

 

The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Moreover, increasing immunization programs, growing awareness about the disease, and increasing R&D activities pertaining to meningococcal vaccines are expected to fuel the market growth during the forecast period.

 

Gather more insights about the market drivers, restrains and growth of the Global Meningococcal Vaccines Market

 

The overall market experienced a decline in 2020 owing to the COVID-19 pandemic. The net sales of Menactra, Menveo, Nimenrix, Trumenba, and Bexsero were negatively impacted in 2020. However, the market is expected to grow at a positive Y-o-Y growth rate in 2021 due to increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis. For instance, in May 2019, the Ministry of Health of Ireland approved MenACWY vaccine to be provided to thousands of teenagers in Ireland, due to the rising prevalence of meningitis in 2018.

 

Various campaigns and awareness programs are being organized by government & non-government organizations, such as the National Meningitis Association (NMA), Meningitis Research Foundation of Canada, Meningitis B Action Project, and others. These organizations help in promoting continuous research and new approaches involved in disease prevention. Hence, these factors are anticipated to fuel the meningococcal vaccine market growth in the coming years.

 

The presence of non-profit organizations providing support for research projects, training to healthcare professionals, and offering information & help to patients is anticipated to accelerate market growth. For instance, in August 2021, DoSomething.Org and National Foundation for Infectious Diseases (NFID) introduced the “Complete What’s Missing Program”. The program’s goal is to educate young people about the importance of Meningococcal Disease Prevention.

 

The presence of phase III vaccines in the pipeline which are expected to be commercialized over the forecast period is anticipated to fuel the market growth. For instance, in June 2020, Pfizer, Inc. initiated phase III clinical trials of PF-06886992, a pentavalent meningococcal vaccine candidate (MenABCWY) to assess & compare the safety, immunogenicity, and tolerability with licensed meningococcal vaccines in adolescents and young adults. Moreover, Menactra, a conjugate vaccine manufactured by Serum Institute of India Pvt. Ltd. is currently in phase III clinical trial.

 

Browse through Grand View Research’s Pharmaceuticals Industry Research Reports.

• Aptamers Market: The global aptamers market size was valued at USD 1,624.5 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 23.5% from 2022 to 2030.
• Intravenous Immunoglobulin Market: The global intravenous immunoglobulin market size was valued at USD 11.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.3% from 2022 to 2030.

 

Meningococcal Vaccines Market Segmentation

Grand View Research has segmented the meningococcal vaccines market based on type, brand, serotype, age group, sales channel, and region:

Meningococcal Vaccines Type Outlook (Revenue, USD Million; 2018 – 2030)

• Bivalent
• Quadrivalent
• Others

Meningococcal Vaccines Brand Outlook (Revenue, USD Million; 2018 – 2030) (Volume, Number of Doses (in Thousands))

• Menactra
• Menveo
• Nimenrix
• Trumenba
• Bexsero
• Others

Meningococcal Vaccines Age Group Outlook (Revenue, USD Million; 2018 – 2030)

• Infants (0 to 2 years)
• Children And Adults (2 years & above)

Meningococcal Vaccines Serotype Outlook (Revenue, USD Million; 2018 – 2030) (Volume, Number of Doses (in Thousands))

• Serotype A
• Serotype B
• Serotype C
• Serotype W-135
• Serotype Y

Meningococcal Vaccines Sales Channel Outlook (Revenue, USD Million; 2018 – 2030)

• Private
• Public

Meningococcal Vaccines Regional Outlook (Revenue, USD Million; 2018 – 2030)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

 

Market Share Insights

• September 2021: WHO and its partners announced the first-ever global strategy to defeat meningitis.
• April 2020: Sanofi received FDA approval for its MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive meningococcal disorders in individuals at least two years old.
• April 2019: Nimenrix was made available for free as a part of the National Immunization Program (NIP) in Australia for the age group 15 to 19 years.

 

Key Companies profiled:

Some prominent players in the global meningococcal vaccines market include:

• Pfizer Inc.
• Sanofi
• Serum Institute of India Ltd.
• GlaxoSmithKline plc.
• Merck & co., Inc.

 

Order a free sample PDF of the Meningococcal Vaccines Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.